Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial

R. A. Lewis; P. S. Clogston; V. Fainstein; R. Gross; T. Samo; C. Tuttle; D. A. Jabs; L. Apuzzo; J. Bartlett; L. C. Coleson; J. P. Dunn; L. Eldred; T. Flynn; R. King; J. Leslie; B. Barron; D. Greenspan; C. LeCount; G. Peyman; R. Franklin; M. H. Heinemann; B. Polsky; K. Squires; A. H. Friedman; T. W. Cheung; N. Justin; H. Sacks; C. Severin; S. Teich; D. N. Friedberg; A. Addessi; D. Dietrich; K. Frost; F. Lafleur; D. V. Weinberg; L. Jampol; R. Murphy; K. Naughton; D. Henderly; N. Holland; S. Chafey; H. Fall; D. Hardy; C. Kimbrell; L. J. MacArthur; W. R. Freeman; L. Meixnert; T. J. Peterson; J. I. Quiceno; L. Rickman; M. A. Simanello; S. Spector; J. O'Donell; T. Bush; J. Hoffman; A. Irvine; M. Jacobson; J. Larson; S. Seiff; M. Wanner; L. Warner; J. Davis; E. Chuang; M. Espinal; P. Mendez; R. Vandenbrouke; S. H. Cheeseman; J. Gittinger; R. Haubrich; H. Kachadoorian; K. Tolson; A. C. Klemm; K. M. Kline; M. Stevens; R. M. Webb; J. Brown-Bellamy; J. A. Markowitz; C. L. Meinert; W. H. Binder; B. J. Collison; J. Dodge; M. Donithan; N. Fink; M. R. Gerzak; C. P. Jones; C. R. Levine; Y. I. Min; J. L. Meinert; D. J. Nowakowski; R. M. Owens; A. Saah; A. L. Sandford; J. Tonascia; M. L. Van Natta; R. L. Mowery; T. Clark; M. D. Davis; J. Korveick; J. Mills

doi:10.1016/S0002-9394(14)71645-9

Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial

R. A. Lewis^*, P. S. Clogston, V. Fainstein, R. Gross, T. Samo, C. Tuttle, D. A. Jabs, L. Apuzzo, J. Bartlett, L. C. Coleson, J. P. Dunn, L. Eldred, T. Flynn, R. King, J. Leslie, B. Barron, D. Greenspan, C. LeCount, G. Peyman, R. FranklinM. H. Heinemann, B. Polsky, K. Squires, A. H. Friedman, T. W. Cheung, N. Justin, H. Sacks, C. Severin, S. Teich, D. N. Friedberg, A. Addessi, D. Dietrich, K. Frost, F. Lafleur, D. V. Weinberg, L. Jampol, R. Murphy, K. Naughton, D. Henderly, N. Holland, S. Chafey, H. Fall, D. Hardy, C. Kimbrell, L. J. MacArthur, W. R. Freeman, L. Meixnert, T. J. Peterson, J. I. Quiceno, L. Rickman, M. A. Simanello, S. Spector, J. O'Donell, T. Bush, J. Hoffman, A. Irvine, M. Jacobson, J. Larson, S. Seiff, M. Wanner, L. Warner, J. Davis, E. Chuang, M. Espinal, P. Mendez, R. Vandenbrouke, S. H. Cheeseman, J. Gittinger, R. Haubrich, H. Kachadoorian, K. Tolson, A. C. Klemm, K. M. Kline, M. Stevens, R. M. Webb, J. Brown-Bellamy, J. A. Markowitz, C. L. Meinert, W. H. Binder, B. J. Collison, J. Dodge, M. Donithan, N. Fink, M. R. Gerzak, C. P. Jones, C. R. Levine, Y. I. Min, J. L. Meinert, D. J. Nowakowski, R. M. Owens, A. Saah, A. L. Sandford, J. Tonascia, M. L. Van Natta, R. L. Mowery, T. Clark, M. D. Davis, J. Korveick, J. Mills

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

PURPOSE: To determine the incidence and risk factors for rhegmatogenous retinal detachment in a population of patients with newly diagnosed cytomegalovirus retinitis. METHODS: Analysis of selected baseline and time- dependent data on patients enrolled in a multicenter, prospective, randomized, controlled clinical trial of therapy with foscarnet vs ganciclovir. RESULTS: In 316 eyes with cytomegalovirus retinitis at baseline, the risk of rhegmatogenous retinal detachment in an eye involved by cytomegalovirus retinitis was 18.9% at 6 months (95% confidence interval [CI], 14.0% to 23.8%) and 37.9% at 1 year (95% CI, 30.5% to 45.3%). Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned. Extent of retinal involvement by cytomegalovirus retinitis, higher patient age, and lower CD4⁺ T-cell counts were associated with an increased risk of retinal detachment; myopia was not. CONCLUSIONS: Retinal detachment in patients with cytomegalovirus retinitis is unrelated to the type of intravenous therapy used or to refractive error. The median time to retinal detachment in an involved eye with cytomegalovirus retinitis and free of retinal detachment at baseline was 18.2 months. Strategies to reduce the extent of retinitis and possibly the number of reactivations may reduce the incidence of retinal detachment.

Original language	English (US)
Pages (from-to)	61-70
Number of pages	10
Journal	American journal of ophthalmology
Volume	124
Issue number	1
DOIs	https://doi.org/10.1016/S0002-9394(14)71645-9
State	Published - 1997

Funding

Supported by cooperative agreements from the National Eye Institute to The Johns Hopkins University School of Medicine (U10 EY 08052), School of Hygiene and Public Health (U10 EY 08057), and the University of Wisconsin School of Medicine (U10 EY 08067). Additional support provided by the National Center for Research Resources through General Clinical Research Center grants 5M01 RR 00350 (Baylor College of Medicine), 5M01 RR 00035 and 5M01 RR 00722 (The Johns Hopkins University), 5M01 RR 05096 (Louisiana State University/ Tulane), 5M01 RR 00071 (Mt Sinai Medical Center), 5M01 RR 00047 (New York Hospital-Cornell Medical Center), 5M01 RR 00096 (New York University), 5M01 RR 00048 (Northwestern University), 5M01 RR 000865 (University of California, Los Angeles), 5M01 RR 00083 (University of California, San Francisco), and 5M01 RR 05280 (University of Miami). Support also provided by the National Institute of Allergy and Infectious Diseases through cooperative agreements UOl AI 27668 (The Johns Hopkins University), UOl AI 27674 (Louisiana State University/Tulane), UOl AI 27669 (Memorial Sloan-Kettering), UOl AI 25917 (New York Hospital-Cornell Medical Center), UOl AI 27667 (Mount Sinai Medical Center), UOl AI 27665 (New York University), UOl AI 25915 (Northwestern University), UOl AI 27660 (University of California, Los Angeles), UOl AI 27670 (University of California, San Diego), UOl AI 27663 (University of California, San Francisco), and UOl AI 25831 (University of Massachusetts). Funding also provided by Astra USA, Inc, Westborough, Massachusetts. Drugs provided by Astra USA, Inc; Burroughs Wellcome Co, Research Triangle Park, North Carolina; and Syntex Research, Palo Alto, California. *AU individuals participating in this study are listed at the end of the article. Financial disclosure statements are on file at the SOCA Coordinating Center, The Johns Hopkins University School of Hygiene and Public Health.

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0002-9394(14)71645-9

Cite this

Lewis, R. A., Clogston, P. S., Fainstein, V., Gross, R., Samo, T., Tuttle, C., Jabs, D. A., Apuzzo, L., Bartlett, J., Coleson, L. C., Dunn, J. P., Eldred, L., Flynn, T., King, R., Leslie, J., Barron, B., Greenspan, D., LeCount, C., Peyman, G., ... Mills, J. (1997). Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial. American journal of ophthalmology, 124(1), 61-70. https://doi.org/10.1016/S0002-9394(14)71645-9

@article{5e266e25eda740aaab2c8be07715b6df,

title = "Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial",

abstract = "PURPOSE: To determine the incidence and risk factors for rhegmatogenous retinal detachment in a population of patients with newly diagnosed cytomegalovirus retinitis. METHODS: Analysis of selected baseline and time- dependent data on patients enrolled in a multicenter, prospective, randomized, controlled clinical trial of therapy with foscarnet vs ganciclovir. RESULTS: In 316 eyes with cytomegalovirus retinitis at baseline, the risk of rhegmatogenous retinal detachment in an eye involved by cytomegalovirus retinitis was 18.9% at 6 months (95% confidence interval [CI], 14.0% to 23.8%) and 37.9% at 1 year (95% CI, 30.5% to 45.3%). Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned. Extent of retinal involvement by cytomegalovirus retinitis, higher patient age, and lower CD4+ T-cell counts were associated with an increased risk of retinal detachment; myopia was not. CONCLUSIONS: Retinal detachment in patients with cytomegalovirus retinitis is unrelated to the type of intravenous therapy used or to refractive error. The median time to retinal detachment in an involved eye with cytomegalovirus retinitis and free of retinal detachment at baseline was 18.2 months. Strategies to reduce the extent of retinitis and possibly the number of reactivations may reduce the incidence of retinal detachment.",

author = "Lewis, {R. A.} and Clogston, {P. S.} and V. Fainstein and R. Gross and T. Samo and C. Tuttle and Jabs, {D. A.} and L. Apuzzo and J. Bartlett and Coleson, {L. C.} and Dunn, {J. P.} and L. Eldred and T. Flynn and R. King and J. Leslie and B. Barron and D. Greenspan and C. LeCount and G. Peyman and R. Franklin and Heinemann, {M. H.} and B. Polsky and K. Squires and Friedman, {A. H.} and Cheung, {T. W.} and N. Justin and H. Sacks and C. Severin and S. Teich and Friedberg, {D. N.} and A. Addessi and D. Dietrich and K. Frost and F. Lafleur and Weinberg, {D. V.} and L. Jampol and R. Murphy and K. Naughton and D. Henderly and N. Holland and S. Chafey and H. Fall and D. Hardy and C. Kimbrell and MacArthur, {L. J.} and Freeman, {W. R.} and L. Meixnert and Peterson, {T. J.} and Quiceno, {J. I.} and L. Rickman and Simanello, {M. A.} and S. Spector and J. O'Donell and T. Bush and J. Hoffman and A. Irvine and M. Jacobson and J. Larson and S. Seiff and M. Wanner and L. Warner and J. Davis and E. Chuang and M. Espinal and P. Mendez and R. Vandenbrouke and Cheeseman, {S. H.} and J. Gittinger and R. Haubrich and H. Kachadoorian and K. Tolson and Klemm, {A. C.} and Kline, {K. M.} and M. Stevens and Webb, {R. M.} and J. Brown-Bellamy and Markowitz, {J. A.} and Meinert, {C. L.} and Binder, {W. H.} and Collison, {B. J.} and J. Dodge and M. Donithan and N. Fink and Gerzak, {M. R.} and Jones, {C. P.} and Levine, {C. R.} and Min, {Y. I.} and Meinert, {J. L.} and Nowakowski, {D. J.} and Owens, {R. M.} and A. Saah and Sandford, {A. L.} and J. Tonascia and {Van Natta}, {M. L.} and Mowery, {R. L.} and T. Clark and Davis, {M. D.} and J. Korveick and J. Mills",

note = "Funding Information: Supported by cooperative agreements from the National Eye Institute to The Johns Hopkins University School of Medicine (U10 EY 08052), School of Hygiene and Public Health (U10 EY 08057), and the University of Wisconsin School of Medicine (U10 EY 08067). Additional support provided by the National Center for Research Resources through General Clinical Research Center grants 5M01 RR 00350 (Baylor College of Medicine), 5M01 RR 00035 and 5M01 RR 00722 (The Johns Hopkins University), 5M01 RR 05096 (Louisiana State University/ Tulane), 5M01 RR 00071 (Mt Sinai Medical Center), 5M01 RR 00047 (New York Hospital-Cornell Medical Center), 5M01 RR 00096 (New York University), 5M01 RR 00048 (Northwestern University), 5M01 RR 000865 (University of California, Los Angeles), 5M01 RR 00083 (University of California, San Francisco), and 5M01 RR 05280 (University of Miami). Support also provided by the National Institute of Allergy and Infectious Diseases through cooperative agreements UOl AI 27668 (The Johns Hopkins University), UOl AI 27674 (Louisiana State University/Tulane), UOl AI 27669 (Memorial Sloan-Kettering), UOl AI 25917 (New York Hospital-Cornell Medical Center), UOl AI 27667 (Mount Sinai Medical Center), UOl AI 27665 (New York University), UOl AI 25915 (Northwestern University), UOl AI 27660 (University of California, Los Angeles), UOl AI 27670 (University of California, San Diego), UOl AI 27663 (University of California, San Francisco), and UOl AI 25831 (University of Massachusetts). Funding also provided by Astra USA, Inc, Westborough, Massachusetts. Drugs provided by Astra USA, Inc; Burroughs Wellcome Co, Research Triangle Park, North Carolina; and Syntex Research, Palo Alto, California. *AU individuals participating in this study are listed at the end of the article. Financial disclosure statements are on file at the SOCA Coordinating Center, The Johns Hopkins University School of Hygiene and Public Health.",

year = "1997",

doi = "10.1016/S0002-9394(14)71645-9",

language = "English (US)",

volume = "124",

pages = "61--70",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

number = "1",

}

Lewis, RA, Clogston, PS, Fainstein, V, Gross, R, Samo, T, Tuttle, C, Jabs, DA, Apuzzo, L, Bartlett, J, Coleson, LC, Dunn, JP, Eldred, L, Flynn, T, King, R, Leslie, J, Barron, B, Greenspan, D, LeCount, C, Peyman, G, Franklin, R, Heinemann, MH, Polsky, B, Squires, K, Friedman, AH, Cheung, TW, Justin, N, Sacks, H, Severin, C, Teich, S, Friedberg, DN, Addessi, A, Dietrich, D, Frost, K, Lafleur, F, Weinberg, DV, Jampol, L , Murphy, R, Naughton, K, Henderly, D, Holland, N, Chafey, S, Fall, H, Hardy, D, Kimbrell, C, MacArthur, LJ, Freeman, WR, Meixnert, L, Peterson, TJ, Quiceno, JI, Rickman, L, Simanello, MA, Spector, S, O'Donell, J, Bush, T, Hoffman, J, Irvine, A, Jacobson, M, Larson, J, Seiff, S, Wanner, M, Warner, L, Davis, J, Chuang, E, Espinal, M, Mendez, P, Vandenbrouke, R, Cheeseman, SH, Gittinger, J, Haubrich, R, Kachadoorian, H, Tolson, K, Klemm, AC, Kline, KM, Stevens, M, Webb, RM, Brown-Bellamy, J, Markowitz, JA, Meinert, CL, Binder, WH, Collison, BJ, Dodge, J, Donithan, M, Fink, N, Gerzak, MR, Jones, CP, Levine, CR, Min, YI, Meinert, JL, Nowakowski, DJ, Owens, RM, Saah, A, Sandford, AL, Tonascia, J, Van Natta, ML, Mowery, RL, Clark, T, Davis, MD, Korveick, J & Mills, J 1997, 'Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial', American journal of ophthalmology, vol. 124, no. 1, pp. 61-70. https://doi.org/10.1016/S0002-9394(14)71645-9

TY - JOUR

T1 - Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis

T2 - The foscarnet-ganciclovir cytomegalovirus retinitis trial

AU - Lewis, R. A.

AU - Clogston, P. S.

AU - Fainstein, V.

AU - Gross, R.

AU - Samo, T.

AU - Tuttle, C.

AU - Jabs, D. A.

AU - Apuzzo, L.

AU - Bartlett, J.

AU - Coleson, L. C.

AU - Dunn, J. P.

AU - Eldred, L.

AU - Flynn, T.

AU - King, R.

AU - Leslie, J.

AU - Barron, B.

AU - Greenspan, D.

AU - LeCount, C.

AU - Peyman, G.

AU - Franklin, R.

AU - Heinemann, M. H.

AU - Polsky, B.

AU - Squires, K.

AU - Friedman, A. H.

AU - Cheung, T. W.

AU - Justin, N.

AU - Sacks, H.

AU - Severin, C.

AU - Teich, S.

AU - Friedberg, D. N.

AU - Addessi, A.

AU - Dietrich, D.

AU - Frost, K.

AU - Lafleur, F.

AU - Weinberg, D. V.

AU - Jampol, L.

AU - Murphy, R.

AU - Naughton, K.

AU - Henderly, D.

AU - Holland, N.

AU - Chafey, S.

AU - Fall, H.

AU - Hardy, D.

AU - Kimbrell, C.

AU - MacArthur, L. J.

AU - Freeman, W. R.

AU - Meixnert, L.

AU - Peterson, T. J.

AU - Quiceno, J. I.

AU - Rickman, L.

AU - Simanello, M. A.

AU - Spector, S.

AU - O'Donell, J.

AU - Bush, T.

AU - Hoffman, J.

AU - Irvine, A.

AU - Jacobson, M.

AU - Larson, J.

AU - Seiff, S.

AU - Wanner, M.

AU - Warner, L.

AU - Davis, J.

AU - Chuang, E.

AU - Espinal, M.

AU - Mendez, P.

AU - Vandenbrouke, R.

AU - Cheeseman, S. H.

AU - Gittinger, J.

AU - Haubrich, R.

AU - Kachadoorian, H.

AU - Tolson, K.

AU - Klemm, A. C.

AU - Kline, K. M.

AU - Stevens, M.

AU - Webb, R. M.

AU - Brown-Bellamy, J.

AU - Markowitz, J. A.

AU - Meinert, C. L.

AU - Binder, W. H.

AU - Collison, B. J.

AU - Dodge, J.

AU - Donithan, M.

AU - Fink, N.

AU - Gerzak, M. R.

AU - Jones, C. P.

AU - Levine, C. R.

AU - Min, Y. I.

AU - Meinert, J. L.

AU - Nowakowski, D. J.

AU - Owens, R. M.

AU - Saah, A.

AU - Sandford, A. L.

AU - Tonascia, J.

AU - Van Natta, M. L.

AU - Mowery, R. L.

AU - Clark, T.

AU - Davis, M. D.

AU - Korveick, J.

AU - Mills, J.

N1 - Funding Information: Supported by cooperative agreements from the National Eye Institute to The Johns Hopkins University School of Medicine (U10 EY 08052), School of Hygiene and Public Health (U10 EY 08057), and the University of Wisconsin School of Medicine (U10 EY 08067). Additional support provided by the National Center for Research Resources through General Clinical Research Center grants 5M01 RR 00350 (Baylor College of Medicine), 5M01 RR 00035 and 5M01 RR 00722 (The Johns Hopkins University), 5M01 RR 05096 (Louisiana State University/ Tulane), 5M01 RR 00071 (Mt Sinai Medical Center), 5M01 RR 00047 (New York Hospital-Cornell Medical Center), 5M01 RR 00096 (New York University), 5M01 RR 00048 (Northwestern University), 5M01 RR 000865 (University of California, Los Angeles), 5M01 RR 00083 (University of California, San Francisco), and 5M01 RR 05280 (University of Miami). Support also provided by the National Institute of Allergy and Infectious Diseases through cooperative agreements UOl AI 27668 (The Johns Hopkins University), UOl AI 27674 (Louisiana State University/Tulane), UOl AI 27669 (Memorial Sloan-Kettering), UOl AI 25917 (New York Hospital-Cornell Medical Center), UOl AI 27667 (Mount Sinai Medical Center), UOl AI 27665 (New York University), UOl AI 25915 (Northwestern University), UOl AI 27660 (University of California, Los Angeles), UOl AI 27670 (University of California, San Diego), UOl AI 27663 (University of California, San Francisco), and UOl AI 25831 (University of Massachusetts). Funding also provided by Astra USA, Inc, Westborough, Massachusetts. Drugs provided by Astra USA, Inc; Burroughs Wellcome Co, Research Triangle Park, North Carolina; and Syntex Research, Palo Alto, California. *AU individuals participating in this study are listed at the end of the article. Financial disclosure statements are on file at the SOCA Coordinating Center, The Johns Hopkins University School of Hygiene and Public Health.

PY - 1997

Y1 - 1997

N2 - PURPOSE: To determine the incidence and risk factors for rhegmatogenous retinal detachment in a population of patients with newly diagnosed cytomegalovirus retinitis. METHODS: Analysis of selected baseline and time- dependent data on patients enrolled in a multicenter, prospective, randomized, controlled clinical trial of therapy with foscarnet vs ganciclovir. RESULTS: In 316 eyes with cytomegalovirus retinitis at baseline, the risk of rhegmatogenous retinal detachment in an eye involved by cytomegalovirus retinitis was 18.9% at 6 months (95% confidence interval [CI], 14.0% to 23.8%) and 37.9% at 1 year (95% CI, 30.5% to 45.3%). Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned. Extent of retinal involvement by cytomegalovirus retinitis, higher patient age, and lower CD4+ T-cell counts were associated with an increased risk of retinal detachment; myopia was not. CONCLUSIONS: Retinal detachment in patients with cytomegalovirus retinitis is unrelated to the type of intravenous therapy used or to refractive error. The median time to retinal detachment in an involved eye with cytomegalovirus retinitis and free of retinal detachment at baseline was 18.2 months. Strategies to reduce the extent of retinitis and possibly the number of reactivations may reduce the incidence of retinal detachment.

AB - PURPOSE: To determine the incidence and risk factors for rhegmatogenous retinal detachment in a population of patients with newly diagnosed cytomegalovirus retinitis. METHODS: Analysis of selected baseline and time- dependent data on patients enrolled in a multicenter, prospective, randomized, controlled clinical trial of therapy with foscarnet vs ganciclovir. RESULTS: In 316 eyes with cytomegalovirus retinitis at baseline, the risk of rhegmatogenous retinal detachment in an eye involved by cytomegalovirus retinitis was 18.9% at 6 months (95% confidence interval [CI], 14.0% to 23.8%) and 37.9% at 1 year (95% CI, 30.5% to 45.3%). Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned. Extent of retinal involvement by cytomegalovirus retinitis, higher patient age, and lower CD4+ T-cell counts were associated with an increased risk of retinal detachment; myopia was not. CONCLUSIONS: Retinal detachment in patients with cytomegalovirus retinitis is unrelated to the type of intravenous therapy used or to refractive error. The median time to retinal detachment in an involved eye with cytomegalovirus retinitis and free of retinal detachment at baseline was 18.2 months. Strategies to reduce the extent of retinitis and possibly the number of reactivations may reduce the incidence of retinal detachment.

UR - http://www.scopus.com/inward/record.url?scp=0003179524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0003179524&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(14)71645-9

DO - 10.1016/S0002-9394(14)71645-9

M3 - Article

C2 - 9222234

AN - SCOPUS:0003179524

SN - 0002-9394

VL - 124

SP - 61

EP - 70

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 1

ER -

Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this